Anzeige
Meldung des Tages: Freitagabend nachbörslich veröffentlicht – was der Markt erst am Montag sieht

Halozyme Therapeutics Aktie News

Aktie
WKN:  A0DLHS ISIN:  US40637H1095 US-Symbol:  HALO Branche:  Biotechnologie Land:  USA
71,59 $
-1,74 $
-2,37%
60,411 € 30.01.26
Depot/Watchlist
Marktkapitalisierung *
7,44 Mrd. €
Streubesitz
-
KGV
10,83
neu: Nachhaltigkeits-Score
36 %
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,45: JU6LK7
Werbung

Halozyme Therapeutics News

28.01.26 - PR Newswire
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-​Year Financial Guidance PR Newswire
20.01.26 - PR Newswire
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update PR Newswire
08.01.26 - PR Newswire
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE® PR Newswire
05.01.26 - PR Newswire
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-​Formulated with ENHANZE® for Obesity PR Newswire
18.12.25 - PR Newswire
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-​lpuj) Co-​Formulated with ENHANZE® for the Treatment of Advanced EGFR-​mutated Non-Small Cell ...
16.12.25 - PR Newswire
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B PR Newswire
08.12.25 - PR Newswire
Jim Lang Elected to Halozyme's Board of Directors
Jim Lang Elected to Halozyme's Board of Directors PR Newswire
04.12.25 - PR Newswire
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany PR Newswire
25.11.25 - PR Newswire
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference PR Newswire
18.11.25 - PR Newswire
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery PR Newswire
17.11.25 - PR Newswire
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab PR Newswire
07.11.25 - LYNX Analysen
Plattform statt Risiko: Halozyme auf dem Weg in die Zukunft?
Ausstieg aus der eigenen Forschung, Fokus auf Plattformtechnologie – Halozyme zeigt, wie kluges Strategie-​Management aussieht. Jetzt vollständige Analyse lesen
07.11.25 - PR Newswire
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma PR Newswire
06.11.25 - PR Newswire
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 PR ...
05.11.25 - PR Newswire
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032 PR Newswire
04.11.25 - wallstreetONLINE Redaktion
Hebel-Idee | Long-Chance: Warum ausgerechnet auf Novo Nordisk setzen, wenn diese Aktie so viel besser ist?
Während viele Anlegerinnen und Anleger verzweifelt auf einen Turnarnound der Aktie von Novo Nordisk warten, hat Halozyme schon jetzt deutlich mehr zu bieten. Willkommen zum ...
03.11.25 - PR Newswire
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS PR Newswire
21.10.25 - PR Newswire
Halozyme to Report Third Quarter 2025 Financial and Operating Results
Halozyme to Report Third Quarter 2025 Financial and Operating Results PR Newswire
01.10.25 - PR Newswire
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s PR Newswire
28.08.25 - PR Newswire
Halozyme to Participate at Upcoming Investor Conferences
Halozyme to Participate at Upcoming Investor Conferences PR Newswire

Newssuche

Videos

newspaper
29.01.26 -10,12%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »